Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analy...(aldelayed release formulation delivering...),Health

Additional TAK-390MR data being presented at ACG includes:

-- Long-Term Safety of TAK-390MR, a PPI with a Novel Dual Delayed Release

Formulation, in GERD Patients.

Abstract P391, Poster Presentation, Monday, October 6

-- Placebo-Controlled Trial of Two Doses of TAK-390MR, a PPI with Novel

Dual Delayed Release Technology, as Maintenance Treatment for Patients

with Healed Erosive Esophagitis (EE).

Abstract P21, Poster Presentation, Sunday, October 5

-- TAK-390MR Maintains Relief of Gastroesophageal Reflux Disease (GERD)

Symptoms and Improvements in Quality of Life in GERD Patients with

Healed Erosive Esophagitis.

Abstract P24, Poster Presentation, Sunday October 5

-- TAK-390MR, a Novel Dual Delayed Release Formulation of a PPI, is

Bioequivalent When Administered as Granules Sprinkled Over Applesauce

or as an Intact Capsule.

Abstract P394, Poster, Monday, October 6

About TAK-390MR

TAK-390MR, an investigational compound, is currently under review with the U.S. Food and Drug Administration (FDA) for once-daily, oral treatment of daytime and nighttime heartburn and other symptoms of Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis and the maintenance of healed erosive esophagitis. TAK-390MR combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of drug for extended duration of acid suppression. The New Drug Application for TAK-390MR was based on global studies conducted in 20 countries, in approximately 6,000 patients with erosive and non-erosive GERD. The most commonly reported treatment-related adverse reactions (greater than or equal to 1%) in Phase 3 clinical trials were diarrhea (3.6%), abdominal pain (2.1%) and flatulence (1.1%).

'/>"/>